Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/ijms21072528
Keywords
AML; CDK6; palbociclib; MLL-AF9; FLT3; RUNX1-ETO; JAK2-V617F
Funding
- Fund of City of Vienna for innovative, interdisciplinary cancer research
- European Research Council under the European Union's Horizon 2020 research and innovation program [694354]
- Austrian Science Foundation (FWF) [P 31773]
Ask authors/readers for more resources
Acute myeloid leukemia (AML) is a complex disease with an aggressive clinical course and high mortality rate. The standard of care for patients has only changed minimally over the past 40 years. However, potentially useful agents have moved from bench to bedside with the potential to revolutionize therapeutic strategies. As such, cell-cycle inhibitors have been discussed as alternative treatment options for AML. In this review, we focus on cyclin-dependent kinase 6 (CDK6) emerging as a key molecule with distinct functions in different subsets of AML. CDK6 exerts its effects in a kinase-dependent and -independent manner which is of clinical significance as current inhibitors only target the enzymatic activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available